Log in

Relevant bibliographies by topics / Troponina T / Journal articles

To see the other types of publications on this topic, follow the link: Troponina T.

Journal articles on the topic 'Troponina T'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Troponina T.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Correia, Luis Cláudio Lemos, Fábio L. Sodré, José C. C. Lima, Michael Sabino, Mariana Brito, Guilherme Garcia, Mayara Maraux, Alexandre C. Sousa, Márcia Noya Rabelo, and J. Péricles Esteves. "Valor prognóstico da troponina I de alta sensibilidade versus troponina T nas síndromes coronarianas agudas." Arquivos Brasileiros de Cardiologia 98, no. 5 (May 2012): 406–12. http://dx.doi.org/10.1590/s0066-782x2012005000034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Velilla Moliner, Joaquín, Daniel Lahoz Rodríguez, Antonio Giménez Valverde, and Eduardo Bustamante Rodríguez. "Detección de troponina T ultrasensible en pacientes con riesgo cardiovascular." Revista Española de Cardiología 70, no. 7 (July 2017): 615. http://dx.doi.org/10.1016/j.recesp.2017.01.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Yasri, Sora, and Viroj Wiwanitkit. "Troponina-T e Peptídeo Natriurético tipo B na COVID-19." Arquivos Brasileiros de Cardiologia 116, no. 4 (April 2021): 854. http://dx.doi.org/10.36660/abc.20201191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Alquézar Arbé, Aitor, Miguel Santaló Bel, and Alessandro Sionis. "Interpretación clínica de la determinación de troponina T de elevada sensibilidad." Medicina Clínica 145, no. 6 (September 2015): 258–63. http://dx.doi.org/10.1016/j.medcli.2014.11.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Álvarez Nozal, Isabel, Héctor García Pardo, and Diego Martín Raymondi. "Detección de troponina T ultrasensible en pacientes con riesgo cardiovascular. Respuesta." Revista Española de Cardiología 70, no. 7 (July 2017): 616. http://dx.doi.org/10.1016/j.recesp.2017.02.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Calvo-Cuervo, David, Vicente Barriales-Álvarez, José M. Vegas-Valle, and María Martín-Fernández. "Falsa determinación de troponina T en el contexto de enfermedades inmunológicas." Medicina Clínica 127, no. 11 (September 2006): 437. http://dx.doi.org/10.1157/13092772.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Basquiera, Ana L., Ricardo Capra, Mirtha Omelianiuk, Marcos Amuchástegui, Roberto J. Madoery, and Oscar A. Salomone. "Concentraciones séricas de troponina T en pacientes con enfermedad de Chagas crónica." Revista Española de Cardiología 56, no. 7 (January 2003): 742–44. http://dx.doi.org/10.1016/s0300-8932(03)76947-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Pastor, Gemma, José Alberto San Román, José Luis Vega, Ana María Serrador, Valeriu Epureanu, Raquel Teresa Palomino, Olga Sanz, et al. "Ecocardiografía de estrés con dobutamina y troponina T como marcador de daño miocárdico." Revista Española de Cardiología 55, no. 5 (January 2002): 469–73. http://dx.doi.org/10.1016/s0300-8932(02)76637-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gimeno, Juan R., Lorenzo Monserrat, Inmaculada Pérez-Sánchez, Francisco Marín, Luis Caballero, Manuel Hermida-Prieto, Alfonso Castro, and Mariano Valdés. "Miocardiopatía hipertrófica. Estudio del gen de la troponina T en 127 familias españolas." Revista Española de Cardiología 62, no. 12 (December 2009): 1473–77. http://dx.doi.org/10.1016/s0300-8932(09)73136-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Álvarez, Isabel, Luis Hernández, Héctor García, Vicente Villamandos, María Gracia López, Jorge Palazuelos Molinero, and Diego Martín Raymondi. "Troponina T ultrasensible en pacientes asintomáticos de muy alto riesgo cardiovascular. Registro TUSARC." Revista Española de Cardiología 70, no. 4 (April 2017): 261–66. http://dx.doi.org/10.1016/j.recesp.2016.08.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Oliveira, Manoel D. C., Juliana Álvares, and Maria Consolação V. Moreira. "Dosagem única de troponina cardíaca T prediz risco adverso na insuficiência cardíaca descompensada." Arquivos Brasileiros de Cardiologia 94, no. 4 (April 2010): 527–34. http://dx.doi.org/10.1590/s0066-782x2010005000013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lahoz-Tornos, Álvaro, Juan A. Vilchez-Aguilera, Diana Hernandez-Romero, Ana I. Romero-Aniorte, Esteban Orenes-Piñero, Ruben Jara-Rubio, Ana del Saz-Ortiz, et al. "Colesterol HDL y troponina T ultrasensible como biomarcadores predictivos de fibrilación auricular postoperatoria." Archivos de Cardiología de México 85, no. 2 (April 2015): 111–17. http://dx.doi.org/10.1016/j.acmx.2014.12.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Muñoz Pérez, Mar, Lourdes Mancebo Aragoneses, Ana Arpa Fernández, and Cristina de Ancos Aracil. "Relación de los valores intermedios de troponina T con el diagnóstico de enfermedad cardíaca." Medicina Clínica 124, no. 18 (May 2005): 692–94. http://dx.doi.org/10.1157/13075093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Correia, Luis C. L., Carolina E. Barbosa, Thais Cerqueira, Ana Vasconcelos, Saulo Merelles, Tiago Reis, José C. Lima, J. Péricles Esteves, and Marcela S. Teixeira. "Disfunção renal moderada não está associada a Troponina T elevada em síndromes coronarianas agudas." Arquivos Brasileiros de Cardiologia 95, no. 5 (October 2010): 600–605. http://dx.doi.org/10.1590/s0066-782x2010001500007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Correia, Luis C. L., Carolina E. Barbosa, Thais Cerqueira, Ana Vasconcelos, Saulo Merelles, Tiago Reis, José C. Lima, J. Péricles Esteves, and Marcela S. Teixeira. "Disfunção renal moderada não está associada a Troponina T elevada em síndromes coronarianas agudas." Arquivos Brasileiros de Cardiologia 95, no. 5 (October 2010): 600–605. http://dx.doi.org/10.1590/s0066-782x2010005000111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Martinez, Victor, Aníbal Alfonso Teherán Valderrama, Gina González, Juan Carlos Hernández, Alejandra Caicedo, Norma Montoya, and Liliana Villamil. "Sesgo en la estratificación del síndrome coronario agudo al calcular el grace- score con 1ª, 2ª o troponina Δ." Revista Cuarzo 24, no. 2 (January 10, 2019): 20–26. http://dx.doi.org/10.26752/cuarzo.v24.n2.353.

Full text

Abstract:

Background: Acute coronary syndrome (ACS) is the first cause of mortality in Colombia. An erroneous risk stratification, in the emergency room (ER), affects the interventions performed and the rate of major cardiovascular adverse events. We measured the difference in GRACE score and stratification of coronary risk, by using the results of troponins measured sequentially during initial care. Methods: With a retrospective descriptive design, clinical records of patients treated for precordial pain of ≥ intermediate probability for ACS were evaluated, without indication of immediate invasive management, attended in the ER of a clinic of the third level of Bogotá, during 2017. Determined the difference between the GRACE score calculated with the first (GRACE-1), second (GRACE-2) or troponin delta (GRACE-delta) [paired T-test], and the proportion of poorly stratified patients was measured when using the first troponin [X2, Z-score]. Results: 44 patients in a period of 6 months were identified. The majority men, older adults, middle age 73 years. The average (SD) of scores GRACE-1, GRACE-2 and GRACE-delta, was 114.14 (30.73), 115.55 (30.14) and 111.11 (28.79), respectively; when comparing GRACE-delta with GRACE-1 and GRACE-2 significant differences were identified (p: <0.05). Error in the stratification of coronary risk was identified in 10/44 patients (22.7%), and 9/44 (20.4%) presented over-stratification. Conclusion: The stratification of coronary risk using the first troponin, unlike the troponin delta (item not clarified in the guidelines), evidenced an over-stratification in at least 20% of the patients, establishing the need for more invasive procedures and possibly longer hospital stay.

APA, Harvard, Vancouver, ISO, and other styles

17

Machado, Maurício de Nassau, Fábio Augusto Suzuki, Osana Costa C. Mouco, Mauro Esteves Hernandes, Maria Angélica B. T. Lemos, and Lilia Nigro Maia. "Troponina T positiva em paciente chagásico com taquicardia ventricular sustentada e cinecoronariografia sem lesões obstrutivas." Arquivos Brasileiros de Cardiologia 84, no. 2 (February 2005): 182–84. http://dx.doi.org/10.1590/s0066-782x2005000200019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cotugno, Marilena, Jacinto Orgaz-Molina, Vladimir Rosa-Salazar, Leticia Guirado-Torrecillas, and Bartolomé García-Pérez. "Disfunción del ventrículo derecho en la embolia pulmonar aguda: NT-proBNP frente a troponina T." Medicina Clínica 148, no. 8 (April 2017): 339–44. http://dx.doi.org/10.1016/j.medcli.2016.11.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Ferrer-Sistach, Elena, Josep Lupón, Germán Cediel, Elena Revuelta-López, and Antoni Bayés-Genís. "Dinámica de troponina T de alta sensibilidad y pronóstico en pacientes con estenosis aórtica grave asintomática." Revista Española de Cardiología 73, no. 12 (December 2020): 1065–66. http://dx.doi.org/10.1016/j.recesp.2020.04.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Pascual-Figal, Domingo A., Sergio Manzano-Fernández, Francisco Pastor, Iris P. Garrido, Teresa Casas, Jesús Sánchez Mas, Pilar Ansaldo, Pedro Martínez, and Mariano Valdés. "Valor de la determinación seriada de troponina T en pacientes ambulatorios con insuficiencia cardiaca no isquémica." Revista Española de Cardiología 61, no. 7 (July 2008): 678–86. http://dx.doi.org/10.1157/13123988.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Santotoribio, J. D., A. León-Justel, and J. M. Guerrero. "Determinación de mioglobina y troponina T en suero para el diagnóstico precoz del infarto agudo de miocardio." Revista Clínica Española 209, no. 3 (March 2009): 152–53. http://dx.doi.org/10.1016/s0014-2565(09)70885-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ripoll-Vera, Tomás, José María Gámez, Nancy Govea, Yolanda Gómez, Juana Núñez, Lorenzo Socías, Ángela Escandell, and Jorge Rosell. "Perfil clínico y pronóstico de las miocardiopatías causadas por mutaciones en el gen de la troponina T." Revista Española de Cardiología 69, no. 2 (February 2016): 149–58. http://dx.doi.org/10.1016/j.recesp.2015.06.028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Escribano, D., E. Santas, G. Miñana, A. Mollar, S. García-Blas, E. Valero, A. Payá, F. J. Chorro, J. Sanchis, and J. Núñez. "Troponina T de alta sensibilidad y riesgo de hospitalizaciones recurrentes tras un ingreso por insuficiencia cardíaca aguda." Revista Clínica Española 217, no. 2 (March 2017): 63–70. http://dx.doi.org/10.1016/j.rce.2016.10.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Almeida, Gustavo Luiz Gouvêa de, Fabricio Braga, José Kezen Jorge, Gustavo Freitas Nobre, Marcelo Kalichsztein, Paula de Medeiros Pache de Faria, Bruno Bussade, et al. "Valor Prognóstico da Troponina T e do Peptídeo Natriurético Tipo B em Pacientes Internados por COVID-19." Arquivos Brasileiros de Cardiologia 115, no. 4 (October 2020): 660–66. http://dx.doi.org/10.36660/abc.20200385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Roldán Torres, Ildefonso, Pascual Baello Monge, Begoña Sevilla Toral, Antonio Salvador Sanz, Miriam Salim Martínez, Antonio Peláez González, Vicente Mora Llabata, et al. "Valor pronóstico de la troponina T en pacientes hospitalizados con angina o infarto sin elevación del segmento ST." Revista Española de Cardiología 56, no. 1 (January 2003): 35–42. http://dx.doi.org/10.1016/s0300-8932(03)76819-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Méndez, Ana B., Montserrat Cardona, Jorge Ordóñez-Llanos, Sònia Mirabet, Felix Perez-Villa, and Eulàlia Roig. "Valor predictivo de la troponina T de alta sensibilidad para descartar el rechazo agudo tras un trasplante cardiaco." Revista Española de Cardiología 67, no. 9 (September 2014): 775–76. http://dx.doi.org/10.1016/j.recesp.2014.04.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Sierra, Ana Paula, Nabil Ghorayeb, Giuseppe Sebastiano Dioguardi, Carlos Anibal Sierra, and Maria Augusta Peduti Dal Molin Kiss. "Alteração de biomarcadores de lesão miocárdica em atletas após a Maratona Internacional de São Paulo." Revista Brasileira de Medicina do Esporte 21, no. 3 (June 2015): 182–86. http://dx.doi.org/10.1590/1517-86922015210302223.

Full text

Abstract:

INTRODUÇÃO: Apesar de a prática regular de exercício físico reduzir o risco de doença cardiovascular, estudos recentes têm documentado elevações em biomarcadores relacionados com danos cardíacos após exercícios prolongados em indivíduos aparentemente saudáveis. OBJETIVO: Investigar as alterações nos níveis de brain natriuretic peptide (BNP) e troponina T cardíaca (cTnT) em atletas amadores após uma maratona, assim como verificar as possíveis relações entre as alterações, antes e depois da prova, apresentada pelos dois biomarcadores e variáveis do teste cardiopulmonar. MÉTODOS: Estudamos 38 atletas do sexo masculino (40,9 ± 6,29 anos) antes e depois da Maratona Internacional de São Paulo, SP, Brasil. Foram realizadas coletas de sangue na veia antecubital para mensurar os biomarcadores cardíacos, cTnT e BNP 24h antes, imediatamente após e 24h após a maratona. Foi realizado teste cardiopulmonar máximo nas três semanas que antecederam a prova. RESULTADOS: Os valores de BNP e cTnT aumentaram imediatamente após a maratona (p<0,001) quando comparados com os valores basais. No terceiro momento (24h) os valores de troponina tiveram uma redução significativa caracterizando um retorno aos valores basais. Não encontramos correlação entre idade e variáveis referentes a intensidade da maratona, porém encontramos correlação dos biomarcadores com o tempo de conclusão da maratona. CONCLUSÃO: Diferentes causas de liberação podem ser assumidas para cTnT e BNP e, neste caso, parecem não refletir dano miocárdico devido ao comportamento da curva destes marcadores, além de não haver relação entre a liberação dos dois biomarcadores.

APA, Harvard, Vancouver, ISO, and other styles

28

Costabel, Juan, Diego Conde, Florencia Lambardi, Andrea Corrales Barboza, Augusto Lavalle Cobo, Martín Aragón, and Marcelo Trivi. "Evaluación de un nuevo algoritmo diagnóstico para el síndrome coronario agudo con determinación de troponina T de alta sensibilidad." Revista Argentina de Cardiología 82, no. 4 (October 2014): 316–21. http://dx.doi.org/10.7775/rac.es.v82.i4.3650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bañón González, Rafael, Esperanza Navarro Escayola, José A. Noguera Velasco, Lina Benali, and Eduardo Osuna Carrillo de Albornoz. "Utilidad de la determinación de troponina T, CK-MB, NT-proBNP y mioglobina en humor vítreo en autopsias forenses." Revista Española de Medicina Legal 34, no. 1 (January 2008): 18–24. http://dx.doi.org/10.1016/s0377-4732(08)70022-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Muñoz-Esparza, Carmen, Iris P. Garrido, Rosa Blanco, Teresa Casas, Cristina González-Cánovas, Francisco Pastor-Pérez, Pablo Peñafiel, Alfredo Minguela, Mariano Valdés, and Domingo A. Pascual-Figal. "Utilidad de la prueba de troponina T de alta sensibilidad en la detección de rechazo agudo en trasplante cardiaco." Revista Española de Cardiología 64, no. 12 (December 2011): 1109–13. http://dx.doi.org/10.1016/j.recesp.2011.06.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ndrepepa, Gjin, Siegmund Braun, Salvatore Cassese, Katharina Mayer, Raphaela Lohaus, Anna L. Lahmann, Massimiliano Fusaro, Karl-Ludwig Laugwitz, Heribert Schunkert, and Adnan Kastrati. "Valor pronóstico de la troponina T de alta sensibilidad tras intervención coronaria percutánea en pacientes con enfermedad coronaria estable." Revista Española de Cardiología 69, no. 8 (August 2016): 746–53. http://dx.doi.org/10.1016/j.recesp.2016.02.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Mejía Sandoval, Harvey Julián, and Jorge Mario Palmezano Díaz. "Infarto agudo de miocardio sin enfermedad coronaria obstructiva, secundaria a tirotoxicosis por bocio multinodular tóxico." Archivos Peruanos de Cardiología y Cirugía Cardiovascular 2, no. 1 (January 2, 2021): 62–66. http://dx.doi.org/10.47487/apcyccv.v2i1.90.

Full text

Abstract:

El infarto agudo de miocardio en ausencia de enfermedad coronaria obstructiva (MINOCA) representa un reto diagnóstico en la práctica clínica. En su abordaje diagnóstico se incluye la documentación de un sustrato isquémico, con un tratamiento que debe ser específico según la etiología identificada. Un grupo de estos pacientes presenta isquemia secundaria a una alteración en la relación aporte/ demanda de oxígeno. Se presenta el caso de una paciente de sexo femenino y mediana edad, con hipertiroidismo severo y tirotoxicosis, que debuta con un síndrome coronario agudo, con troponina T marcadamente elevada y arterias coronarias sin lesiones significativas en la coronariografía. El tratamiento fue dirigido a manejar la causa desencadenante, de manera inicialmente farmacológica y posteriormente quirúrgica, con resolución total del cuadro, mejoría sintomática de la paciente y disminución de los biomarcadores cardíacos.

APA, Harvard, Vancouver, ISO, and other styles

33

Capdevila, Carmen, Manuel Portolés, Amparo Hernándiz, Vicente Pallarés, and Juan Cosín. "La troponina T como posible marcador del daño miocárdico menor. Su aplicación en el miocardio aturdido y en la isquemia silente." Revista Española de Cardiología 54, no. 5 (January 2001): 580–91. http://dx.doi.org/10.1016/s0300-8932(01)76360-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Eidizadeh, Abass, Laura Fraune, Andreas Leha, Rolf Wachter, Abdul R. Asif, and Lutz Binder. "Inconsistent Findings of Cardiac Troponin T and I in Clinical Routine Diagnostics: Factors of Influence." Journal of Clinical Medicine 10, no. 14 (July 16, 2021): 3148. http://dx.doi.org/10.3390/jcm10143148.

Full text

Abstract:

Cardiac troponins are crucial for the diagnosis of acute myocardial infarction. Despite known differences in their diagnostic implication, there are no recommendations for only one of the two troponins, cardiac troponin I (cTnI) and troponin T (cTnT) so far. In an everyday routine diagnostic, cTnT (Roche) as well as cTnI (Abbott) were measured in 5667 samples from 3264 patient cases. We investigated the number of identical or discrepant troponin findings. Regarding cTnI, we considered both, sex-dependent and unisex cutoffs. In particular, the number of cTnT positive and cTnI negative results was strikingly high in 14.0% of cTnT positive samples and increases to 23.8% by using sex-specific cTnI cutoffs. This group was considerably greater than the group of cTnI positive and cTnT negative results, also after elimination of patients with an eGFR < 60 mL/min/1.73 m2. Comparing the troponin cases with a dynamic increase or decrease between two measurements, we saw a balanced number of discrepant cases (between cTnT+/cTnI− and cTnT−/cTnI+), which was, however, still present. Using ROC analysis, sex-dependent cutoffs improved sensitivity and specificity of cTnI. This study shows in a large cohort that comparing the two cardiac troponins does not amount to identical analytical results. Consideration of sex-dependent cutoffs may improve sensitivity and specificity.

APA, Harvard, Vancouver, ISO, and other styles

35

Esteve, Sara, Isabel Aleixandre, and Antonio Guerrero. "Utilidad de la troponina T y de la isoenzima 2 de la creatincinasa en el diagnóstico del infarto agudo de miocardio en urgencias." Revista del Laboratorio Clínico 2, no. 3 (July 2009): 124–30. http://dx.doi.org/10.1016/j.labcli.2009.04.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Ferreira, Izabella Guedes, Ana Carolina Tassara Azevedo, Ana Flávia Amaral Durigueto, Isabella Maise de Andrade Rodrigues Sóter, Juliana de Oliveira Miranda Simões, Laura Lustosa Soares, and Thiago Santiago Ferreira. "COVID-19 e miocardite: uma possível consequência cardíaca após a infecção pelo SARS-CoV-2." Revista Eletrônica Acervo Saúde 13, no. 9 (September 5, 2021): e8454. http://dx.doi.org/10.25248/reas.e8454.2021.

Full text

Abstract:

Objetivo: Revisar sobre a relação entre a COVID-19 e a miocardite, levando em consideração os mecanismos fisiopatológicos, métodos diagnósticos e abordagem terapêutica. Revisão bibliográfica: O SARS-CoV-2 pode invadir o organismo do hospedeiro e desenvolver um quadro composto por três fases: a fase inicial da infecção, a pulmonar e a de super inflamação. É nessa última, que geralmente ocorrem os danos ao sistema cardiovascular, em que o vírus se prolifera no sistema imunológico e invade os cardiomiócitos, ocasionando uma inflamação miocárdica e remodelação cardíaca e, consequentemente, a cardiomiopatia. Exames complementares como ecocardiografia transtorácica, eletrocardiograma, dosagem da troponina T ultrassensível e a ressonância magnética cardíaca são importantes na investigação diagnóstica da miocardite. Quanto ao tratamento, deve-se levar em consideração o quadro clínico do paciente e envolve terapias de suporte e objetiva alívio sintomático. Considerações finais: A miocardite é uma complicação cardiológica da infecção pelo SARS-CoV-2 cada vez mais relatada, sendo fundamental, por parte do profissional de saúde, o conhecimento da fisiopatologia e quadro clínico característico da doença, bem como os fatores de risco relacionados, para diagnóstico e intervenções precoces.

APA, Harvard, Vancouver, ISO, and other styles

37

Ferreira, João Pedro, Mário Santos, Sofia Almeida, Irene Marques, Paulo Bettencourt, and Henrique Carvalho. "High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients." Cardiology Research and Practice 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/269604.

Full text

Abstract:

Background.Patients presenting with acutely decompensated heart failure (ADHF) and positive circulating cardiac troponins were found to be a high-risk cohort. The advent of high-sensitive troponins resulted in a detection of positive troponins in a great proportion of heart failure patients. However, the pathophysiological significance of this phenomenon is not completely clear.Objectives.The aim of this study is to determine the early evolution and clinical significance of high-sensitivity troponin T (hsTnT) in ADHF.Methods.Retrospective, secondary analysis of a prospective study including 100 patients with ADHF.Results.Globally, high-sensitivity troponin T decreased from day 1 to day 3(P=0,039). However, in the subgroup of patients who remained decompensated no significant differences in hsTnT from day 1 to day 3 were observed(P=0,955), whereas in successfully compensated patients a significant reduction in hsTnT levels was observed(P=0,025). High-sensitivity troponin T decrease was correlated with NTproBNP reduction(P=0,007). Patients with hsTnT increase had longer length of stay(P=0,033).Conclusions.Episodes of ADHF are associated with transient increases in the blood levels of hsTnT that are reduced with effective acute episode treatment. The decrease in hsTnT can translate less myocardial damage along with favourable ADHF treatment.

APA, Harvard, Vancouver, ISO, and other styles

38

Labugger, Ralf, Jeremy A. Simpson, Michelle Quick, Heather A. Brown, Christine E. Collier, Irina Neverova, and Jennifer E. Van Eyk. "Strategy for Analysis of Cardiac Troponins in Biological Samples with a Combination of Affinity Chromatography and Mass Spectrometry." Clinical Chemistry 49, no. 6 (June 1, 2003): 873–79. http://dx.doi.org/10.1373/49.6.873.

Full text

Abstract:

Abstract Background: Cardiac troponins are modified during ischemic injury and are found as a heterogeneous mixture in blood of patients with cardiovascular diseases. We present a strategy to isolate cardiac troponins from human biological material, by use of affinity chromatography, and to provide samples ready for direct analysis by mass spectrometry. Methods: Cardiac troponins were isolated from human left ventricular tissue by affinity chromatography. Isolated troponins were either eluted and analyzed by Western blot or enzymatically digested while bound to affinity beads. The resulting peptide mixture was subjected to mass spectrometry for protein identification and characterization. The same method was used to analyze serum from patients with acute myocardial infarction (AMI). Results: Affinity chromatography with antibodies specific for one cardiac troponin subunit facilitated the isolation of the entire cardiac troponin complex from myocardial tissue. The three different proteases used for enzymatic digestion increased the total protein amino acid sequence coverage by mass spectrometry for the three cardiac troponin subunits. Combined amino acid sequence coverages for cardiac troponin I, T, and C (cTnI, cTnT, cTnC) were 54%, 48%, and 40%, respectively. To simulate matrix effects on the affinity chromatography–mass spectrometry approach, we diluted tissue homogenate in cardiac troponin-free serum. Sequence coverages in this case were 44%, 41%, and 19%, respectively. Finally, affinity chromatography–mass spectrometry analysis of AMI serum revealed the presence of cardiac troponins in a wide variety of its free and/or complexed subunits, including the binary cTnI-cTnC and cTnI-cTnC-cTnT complexes. Conclusions: Affinity chromatography–mass spectrometry allows the extraction and analysis of cardiac troponins from biological samples in their natural forms. We were, for the first time, able to directly confirm the presence of cardiac troponin complexes in human serum after AMI. This approach could assist in more personalized risk stratification as well as the search for reference materials for cardiac troponin diagnostics.

APA, Harvard, Vancouver, ISO, and other styles

39

Trofimjak, R., and L. Slivinska. "ДІАГНОСТИКА ХРОНІЧНОЇ СЕРЦЕВОЇ НЕДОСТАТНОСТІ СОБАК – ІСНУЮЧІ МЕТОДИ ТА ПОДАЛЬШІ ПЕРСПЕКТИВИ." Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies 18, no. 3(71) (October 5, 2016): 130–33. http://dx.doi.org/10.15421/nvlvet7129.

Full text

Abstract:

The article analyzes the current scientific work related to the study of processes of chronic heart failure (CHF), and the use of biomarkers in the diagnosis of heart disease in dogs. Thoracic radiography, electrocardiography, and echocardiography are used to diagnose heart disease in dogs but despite the use of non–invasive methods, there is uncertainty about the severity of the disease and prognosis for each patient individually. In veterinary practice for the diagnosis of myocardial lesions in animals are clinically valuable, highly sensitive and simple to use cardiac biomarkers. A biomarker is typically a substance in the blood that can be objectively measured and indicates a biologic or pathologic process or response to therapy.1 There are scores of cardiac biomarkers,but this article will focus on the 2 most clinically useful ones in the dog and cat:cardiac troponin I (cTnI) and N–terminal pro–B–type natriuretic peptide (NT–proBNP). The cardiac troponins I, T, and C (cTnI, cTnT, and cTnC) are thin filament–associated regulatory proteins of the heart muscle. Cardiac troponin I («I» for inhibition) is uniquely expressed in the myocardium and is a potent inhibitor of the process of actin–myosin cross–bridge formation. The molecular weight is 24.000 D. Cardiac troponin T («T» for tropomyosin binding) has a molecular weight of 37.000 D and binds the troponin complex to tropomyosin. Cardiac troponin C («C» for calcium) binds to calcium and starts, therefore, the crossbridge cycle. As with cTnI, approximately 95% of cTnT in man and dogs is myofibril bound and about 5% is cytosolically dissolved. Mechanisms for an elevation in circulating cardiac troponins include an increase of myocyte membrane permeability (initial release of the cytosolic troponin pool) or cell necrosis (release of myofibrilbound troponins). Four to six hours after acute myocardial cell injury, the cardiac troponin concentration in blood increases in a biphasic pattern. Plasma half–life of cardiac troponins is approximately two hours, and elimination mainly occurs via the reticuloendothelial system (cTnI and cTnT) and renal loss (cTnT). Cardiac troponins are phylogenetically highly preserved proteins with a more than 95% total structural agreement between mammals. Therefore, established human serologic tests for troponin analysis may be used reliably in pets as well. Myocardial cell injury, manifested anatomically as inflammation (endomyocarditis, myocarditis, perimyocarditis), acute degeneration, apoptosis, or necrosis or hemodynamically as transient or permanent cardiac contractile dysfunction, is a frequent consequence of physical myocardial trauma (cardiac contusion), cardiomyopathy, metabolic or toxic myocardial damage (anthracyclines, catecholamines, bacterial endotoxins, tumor necrosis factor), myocardial ischemia or infarction. However, early diagnosis of myocardial injury may be important from a therapeutic and prognostic perspective.

APA, Harvard, Vancouver, ISO, and other styles

40

Collinson, Paul O., Frances G. Boa, and David C. Gaze. "Measurement of Cardiac Troponins." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 38, no. 5 (September 2001): 423–49. http://dx.doi.org/10.1177/000456320103800501.

Full text

Abstract:

The cardiac troponins form part of the regulatory mechanism for muscle contraction. Specific cardiac isoforms of cardiac troponin T and cardiac troponin I exist and commercially available immunoassay systems have been developed for their measurement. A large number of clinical and analytical studies have been performed and the measurement of cardiac troponins is now considered the ‘gold standard’ biochemical test for diagnosis of myocardial damage. There have been advances in understanding the development and structure of troponins and their degradation following myocardial cell necrosis. This has contributed to the understanding of the problems with current assays. Greater clinical use has also highlighted areas of analytical and clinical confusion. The assays are reviewed based on manufacturers' information, current published material as well as the authors' in-house experience.

APA, Harvard, Vancouver, ISO, and other styles

41

Chaulin, A., and Yu Grigoryeva. "Main Aspects of Biochemistry, Physiology of Cardiac Troponins." Bulletin of Science and Practice 6, no. 5 (May 15, 2020): 105–12. http://dx.doi.org/10.33619/2414-2948/54/13.

Full text

Abstract:

Cardiac troponins (troponin I, T, and C) play an important role in the regulation of contractile function of the heart muscle. Mutations in cardiac troponins are associated with the development of various types of cardiomyopathies, which lead to heart failure and death. The determination of the concentration of cardiac troponins in the blood is used in the diagnosis of some cardiovascular diseases, including acute myocardial infarction, myocarditis, heart failure. This review summarizes the available data on the structure and functions of cardiac troponins, their role in the regulation of myocardial contractions and clinical application.

APA, Harvard, Vancouver, ISO, and other styles

42

Hijazi, Ziad, Agneta Siegbahn, Ulrika Andersson, Bertil Lindahl, Christopher B. Granger, John H. Alexander, Dan Atar, et al. "Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy." Clinical Chemistry 61, no. 2 (February 1, 2015): 368–78. http://dx.doi.org/10.1373/clinchem.2014.226936.

Full text

Abstract:

Abstract BACKGROUND Although cardiac troponin is associated with outcomes in atrial fibrillation (AF), the complementary prognostic information provided by cardiac troponin I (cTnI) and cTnT is unknown. This study investigated the distribution, determinants, and prognostic value of cTnI and cTnT concentrations in patients with AF. METHODS Samples were collected. At the time of randomization, we analyzed cTnI and cTnT concentrations of 14806 AF patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial using high-sensitivity assays. Correlations (Spearman), determinants (multivariable linear regression), and outcomes (adjusted Cox models and c-statistics) were investigated. RESULTS Concentrations of cTnI and cTnT were correlated (r = 0.70) and measurable in most participants [cTnI 98.5% (median 5.4 ng/L, ≥99th percentile in 9.2%) and cTnT 93.5% (median 10.9 ng/L, ≥99th percentile in 34.4%)]. Renal impairment was the most important factor affecting the concentrations of both troponins. cTnI increase was more associated with heart failure, vascular disease, and persistent/permanent AF, and cTnT with age, male sex, and diabetes. Over a median 1.9 years of follow-up, patients with both troponins above the median had significantly higher risk for stroke/systemic embolism [hazard ratio (HR) 1.72 (95% CI 1.31–2.27)], cardiac death [3.14 (2.35–4.20)], and myocardial infarction [2.99 (1.78–5.03)] than those with both troponins below median (all P < 0.005). Intermediate risks were observed when only 1 troponin was above the median. When combined with clinical information, each marker provided similar prognostication and had comparable c-index. CONCLUSIONS cTnI and cTnT concentrations are moderately correlated and measurable in plasma of most AF patients. The risk of stroke and cardiovascular events is highest when both troponins are above median concentrations. Each troponin provides comparable prognostic information when combined with clinical risk factors. ClinicalTrials.gov/NCT00412984

APA, Harvard, Vancouver, ISO, and other styles

43

Fernández Portales, Javier, José A. García Robles, Javier Jiménez Candil, Esther Pérez David, Juan R. Rey Blas, Leopoldo Pérez de Isla, Óscar Díaz Castro, and Jesús Almendral. "Utilidad clínica de los distintos marcadores biológicos CPK, CPK MB masa, mioglobina y troponina T en una unidad de dolor torácico. ¿Cuándo, cuáles y cómo pedirlos?" Revista Española de Cardiología 55, no. 9 (January 2002): 913–20. http://dx.doi.org/10.1016/s0300-8932(02)76729-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Bian, Yun, Maoyun Sun, Marcy Silver, Kalon K. L. Ho, Mark A. Marchionni, Anthony O. Caggiano, James R. Stone, et al. "Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins." American Journal of Physiology-Heart and Circulatory Physiology 297, no. 6 (December 2009): H1974—H1983. http://dx.doi.org/10.1152/ajpheart.01010.2008.

Full text

Abstract:

Neuregulin-1 (NRG1) is a potential therapeutic agent for the treatment of doxorubicin (Dox)-induced heart failure. NRG1, however, activates the erbB2 receptor, which is frequently overexpressed in breast cancers. It is, therefore, important to understand how NRG1, via erbB2, protects the heart against Dox cardiotoxicity. Here, we studied NRG1-erbB2 signaling in Dox-treated mice hearts and in isolated neonatal rat ventricular myocytes (NRVM). Male C57BL/6 mice were treated with recombinant NRG1 before and daily after a single dose of Dox. Cardiac function was determined by catheterization. Two-week survival was analyzed by the Kaplan-Meier method. Cardiac troponins [cardiac troponin I (cTnI) and cardiac troponin T (cTnT)] and phosphorylated Akt protein levels were determined in mice hearts and in NRVM by Western blot analysis. Activation of caspases and ubiquitinylation of troponins were determined in NRVM by caspase assay and immunoprecipitation. NRG1 significantly improved survival and cardiac function in Dox-treated mice. NRG1 reduced the decrease in cTnI, cTnT, and cardiac troponin C (cTnC) and maintained Akt phosphorylation in Dox-treated mice hearts. NRG1 reduced the decrease in cTnI and cTnT mRNA and proteins in Dox-treated NRVM. Inhibition of erbB2, phosphoinositide 3-kinase (PI3K), Akt, and mTOR blocked the protective effects of NRG1 on cTnI and cTnT in NRVM. NRG1 significantly reduced Dox-induced caspase activation, which degraded troponins, in NRVM. NRG1 reduced Dox-induced proteasome degradation of cTnI. NRG1 attenuates Dox-induced decrease in cardiac troponins by increasing transcription and translation and by inhibiting caspase activation and proteasome degradation of troponin proteins. NRG1 maintains cardiac troponins by the erbB2-PI3K pathway, which may lessen Dox-induced cardiac dysfunction.

APA, Harvard, Vancouver, ISO, and other styles

45

Tarkowska, Agata, and Wanda Furmaga-Jabłońska. "The Evaluation of Cardiac Troponin T in Newborns." Biomedicine Hub 2, no. 3 (October 10, 2017): 1–7. http://dx.doi.org/10.1159/000481086.

Full text

Abstract:

Introduction: In this paper, we evaluated the physiologic ranges of cardiac troponin T (cTnT) serum concentrations in healthy newborns. This is significant because these ranges have not been determined yet, especially for newborns older than 7 days. Cardiac troponins are widely used as diagnostic markers in adults; however, they cannot be routinely used in infants due to lack of data concerning normal values in this age group. Aim: To determine the physiologic ranges of cTnT concentrations in newborns and to evaluate the influence of factors such as age, sex, and blood saturation. Methods: The study involved 59 newborns up to 46 weeks of postmenstrual age (full-term and preterm). The exclusion criteria were severe perinatal asphyxia and presence of severe diseases. Troponin T concentrations were evaluated by the Roche CARDIAC T Quantitative Test. The obtained results were statistically analyzed by the use of the Statistica 9.0 computer program. Results: The study revealed that cTnT levels in newborns correlate with postmenstrual age, but not with chronologic or fetal age. Sex, delivery mode, and blood oxygenation did not influence cTnT concentrations in the studied patients. Conclusions: (1) Cardiac troponin T concentration depends on postmenstrual age in newborns. (2) Cardiac troponin T concentration in newborns does not depend on sex, mode of delivery, or blood saturation.

APA, Harvard, Vancouver, ISO, and other styles

46

Weinmann, Werner, Koenig, Rottbauer, Walcher, and Keßler. "Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy." Biomolecules 9, no. 11 (October 25, 2019): 654. http://dx.doi.org/10.3390/biom9110654.

Full text

Abstract:

Immunoadsorption and subsequent administration of intravenous immunoglobulin (IVIG) have shown beneficial effects on cardiac function and symptoms in patients with dilated cardiomyopathy. Biomarkers play an emerging role in disease monitoring and outcome prediction of heart failure (HF) patients. We aimed to analyze cardiac biomarkers as predictor for improvement of left ventricular (LV) function after immunoadsorption treatment in dilated cardiomyopathy (DCM). Thirty-one patients with dilated cardiomyopathy on optimized HF pharmacotherapy received a single cycle of immunoadsorption for five days followed by IVIG administration. Left ventricular ejection fraction (LVEF) and heart failure biomarkers (hs troponin T, hs troponin I, NT-proBNP and sST2) were evaluated before treatment, after the last cycle of immunoadsorption and during a median follow-up of 30.5 months. We correlated HF biomarkers before immunoadsorption and acute changes of HF biomarkers by immunoadsorption with LV improvement during the long-term follow-up. LV function improved significantly after immunoadsorption from 28.0 to 42.0% during the long-term follow-up (p < 0.0001). Evaluation of biomarker levels showed a significant decrease for hs troponin I (from 9.2 to 5.5 ng/L, p < 0.05) and NT-proBNP (from 789.6 to 281.2 pg/mL, p < 0.005). Correlation of biomarker levels before immunoadsorption and LVEF at the long-term follow-up show good results for hs troponin T (r = −0.40, r2 = 0.16, p < 0.05), hs troponin I (r = −0.41, r2 = 0.17, p < 0.05) and sST2 (r = −0.46, r2 = 0.19, p < 0.05). Correlation of biomarker levels before immunoadsorption and the individual increase in LV function was significant for hs troponin T (r = −0.52, r2 = 0.27, p < 0.005) and hs troponin I (r = −0.53, r2 = 0.29, p < 0.005). To imply a tool for monitoring outcome immediately after immunoadsorption treatment, we investigated the correlation of acute changes of biomarker levels by immunoadsorption treatment and individual increase in LV function. A drop in hs troponin T (r = −0.41, r2 = 0.17, p < 0.05) and hs troponin I (r = −0.53, r2 = 0.28, p < 0.005) levels demonstrate a good correlation to improvement in LVEF during the long-term follow-up. Conclusion: Hs troponin T and I levels correlate with LV function improvement during long-term follow-up. Acute decrease of troponins by immunoadsorption treatment is paralleled by individual improvement of LVEF at the long-term follow-up. Thus, troponins could serve as a monitoring tool for the improvement of LV function after immunoadsorption treatment in dilated cardiomyopathy.

APA, Harvard, Vancouver, ISO, and other styles

47

Stiegler, Hugo, Yuriko Fischer, Jaime F. Vazquez-Jimenez, Jürgen Graf, Karsten Filzmaier, Bernd Fausten, Uwe Janssens, Axel M. Gressner, and Dagmar Kunz. "Lower Cardiac Troponin T and I Results in Heparin-Plasma Than in Serum." Clinical Chemistry 46, no. 9 (September 1, 2000): 1338–44. http://dx.doi.org/10.1093/clinchem/46.9.1338.

Full text

Abstract:

Abstract Background: The use of plasma rather than serum for determination of cardiac troponins can improve turnaround time and potentially avoid incomplete serum separation that may produce falsely increased results. We investigated the influence of incomplete serum separation and the effect of heparin-plasma on cardiac troponin concentrations. Methods: Serum and heparin-plasma samples were drawn simultaneously from 100 patients (50 patients with acute coronary syndrome and 50 patients after open heart surgery) and measured on three different analytical systems, two for determination of cardiac troponin I (cTnI; Abbott AxSYM and Bayer ACS:Centaur) and one for cardiac troponin T (cTnT; Roche Elecsys cTnT STAT). Serum samples were reanalyzed after a second centrifugation to assess the influence of incomplete serum separation. Results: Mean results (± 95% confidence interval) in heparin-plasma compared with serum were 101% ± 2% (AxSYM cTnI), 94% ± 3% (ACS:Centaur cTnI), and 99% ± 3% (Elecsys cTnT). Differences >20% were seen in 11% of results on the ACS:Centaur, 9% of results on Elecsys cTnT, and 2% of results on the AxSYM. For the Elecsys cTnT assay, the magnitude of the difference between serum and plasma was independent of the absolute concentration and confined to individual samples, and was reversed by treatment with heparinase. A second centrifugation had no effect on serum results by any of the assays. Conclusion: The concentrations of troponins measured in heparin-plasma are markedly lower than in serum in some cases.

APA, Harvard, Vancouver, ISO, and other styles

48

Santos, Gilmara Bruschi, Paulo Roberto Rodrigues Ramos, and Jeison Solano Spim. "Alteração nas frações das proteínas miofibrilares e maciez do músculo Longissimus de bovinos no período post mortem." Revista Brasileira de Saúde e Produção Animal 15, no. 4 (December 2014): 1027–37. http://dx.doi.org/10.1590/s1519-99402014000400009.

Full text

Abstract:

Objetivou-se com o estudo identificar por eletroforese as mudanças nas frações das proteínas musculares durante período postmortem de bovinos de diferentes grupos genéticos e analisar a maciez da carne em amostras resfriadas por 24 horas (não maturadas) e maturadas por 7 dias. Foram utilizadas amostras do musculo Longissimus de quarenta e oito bovinos pertencentes a 4 grupos genéticos: 12 Nelore; 12 cruzados ½ Nelore ½ Aberdeen-Angus x Brahman; 12 Brangus; 12 cruzados ½ nelore ½ Aberdeen-Angus x Pardo, submetidos ao modelo biológico superprecoce. De cada uma delas foram retiradas duas fatias, uma não foi maturada e a outra maturada por 7 dias, a 2ºC. Na análise da força de cisalhamento, tanto as amostras não maturadas, quanto as submetidas a 7 dias de maturação não diferiram quanto à maciez da carne, mas todas apresentaram maciez aceitável, o que pode ser explicado pela baixa idade dos animais no momento do abate, o que foi proporcionado pelo sistema de engorda a que estes animais foram submetidos. Na análise das bandas de proteínas da carne, medida pela eletroforese, notou-se degradação da cadeia pesada da miosina e da Troponina -T e o aparecimento do fragmento de 30 kDa para todos os grupos genéticos após o período de 7 dias de maturação.Todos os grupos genéticos apresentaram boa maciez da carne, independentemente do tempo de maturação.

APA, Harvard, Vancouver, ISO, and other styles

49

Braz Amarilio da Cunha, Danielle, Camila Nakamura Perissê Pereira, Yngrid Carneiro de Aguiar, Sarah Godoi de Carvalho, Juliana Barrozo Fernandes Borges, Julia Pinheiro São Pedro, Pedro Henrique Bersan Menezes, Beatriz Moraes Gonçalves, and Fabíola Fernandes dos Santos Castro. "USO DE MARCADORES BIOLÓGICOS PARA AVALIAÇÃO PROGNÓSTICA DE PACIENTES COM COVID-19: UMA REVISÃO DE LITERATURA." RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218 2, no. 6 (July 15, 2021): e26436. http://dx.doi.org/10.47820/recima21.v2i6.436.

Full text

Abstract:

Objetivos: A COVID-19 provoca, principalmente, infecção do trato respiratório inferior, entretanto, alguns pacientes podem cursar com complicações em outros sistemas, exigindo cuidados intensivos. Portanto, dada a variação da severidade dos casos, que vão de quadros assintomáticos a graves, começou-se a estudar os marcadores biológicos como medidas preditivas no prognóstico da doença. Por isso, este estudo teve como objetivo avaliar os principais biomarcadores mencionados na literatura para predizer o prognóstico dos pacientes. Métodos: Fora realizada uma revisão de literatura narrativa, de caráter amplo por meio das bases de dados PUBMED/Medline e SciELO, a fim de descrever os principais biomarcadores que podem ser utilizados na avaliação prognóstica de pacientes com COVID-19. Foram analisados artigos completos e gratuitos, publicados há 1 ano, nas línguas inglesa e portuguesa, de forma que, 40 estudos compuseram a amostra final. Resultados: Analisou-se a albumina, dímero D (DD), desidrogenase lática (DHL), ferritina, fibrinogênio, interleucina 6 (IL-6), linfopenia e neutrofilia, procalcitonina, proteína C reativa (PCR) e troponina cardíaca T e I, caracterizando as peculiaridades de cada um diante da doença. Conclusão: Foi notório o destaque do DD, DHL, IL-6, linfopenia, neutrofilia e PCR como os melhores preditores de gravidade e de pior desfecho da COVID-19. Entretanto, todos estudos mencionados apresentam limitações, sendo necessários mais estudos para avaliação de outros biomarcadores.

APA, Harvard, Vancouver, ISO, and other styles

50

Katus, H. A., and M. Müller-Bardoff. "Kardiales Troponin T (Cardial Troponin T)." Zeitschrift f�r Kardiologie 86, no. 10 (October 1, 1997): 785–87. http://dx.doi.org/10.1007/s003920050116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!